Lupus: Peptide P140/LupuzorTM effectiveness confirmed

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease.

Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide.

Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants.

These results are published online in the .

More information: Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J. and Muller S. Annals of Rheumatic Diseases (doi: 10.1136/annrheumdis-2012-202460)

add to favorites email to friend print save as pdf

Related Stories

Enlisting the AIDS virus to fight cancer

Aug 29, 2012

(Medical Xpress)—Can HIV be transformed into a biotechnological tool for improving human health? According to a CNRS team at the Architecture et Réactivité de l'ARN (RNA Architecture and Reactivity) laboratory, ...

A genetic accelerator hits the gas on autoimmune diseases

Jan 16, 2012

A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the ...

Recommended for you

Drink milk? Women who do may delay knee osteoarthritis

Apr 07, 2014

New research reports that women who frequently consume fat-free or low-fat milk may delay the progression of osteoarthritis (OA) of the knee. Results published in the American College of Rheumatology (ACR) ...

User comments